AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00774800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin-R
Study NCT00774800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study NCT00774800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Study NCT04260347 — intervention group
Intervention type: DRUG
Intervention: Alteplase
Description: Intravenous injection
Study NCT03023293 — intervention group
Intervention type: OTHER
Intervention: n-3 PUFAs consumption and irisin
Description: The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
Study NCT00614146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARS device
Description: 10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
Study NCT00614146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
Study NCT03998488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery.
Study NCT03998488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium Husk Powder
Description: All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat.
Study NCT03998488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Psyllium Husk Powder
Description: All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat.
Study NCT02681094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 5mg, orally, Green, plain, diamond-shaped, film-coated tablet
Study NCT02681094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Dapagliflozin
Description: Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
Study NCT00614146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Description: Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
Study NCT00513942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Movement Counting
Description: Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
Study NCT01119092 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (laying of hands) intervention
Description: The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
Study NCT02681094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
Study NCT02681094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Saxagliptin
Description: Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
Study NCT02534181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Management Protocol
Description: Strategy based on reduction of nutritional intake and electrolyte replacement.
Study NCT01393444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of ECoG sensors on the brain surface
Description: One ECoG sensor will be implanted over the motor cortex of study participants
Study NCT01201902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza A(H1N1) vaccine
Description: 0.25ml, Intramuscular on Day 0 and 21
Study NCT01201902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza A(H1N1) vaccine
Description: 0.5ml, Intramuscular on Day 0 and 21
Study NCT01201902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: un-adjuvanted influenza A(H1N1) vaccine
Description: 0.5ml, Intramuscular on Day 0 and 21
Study NCT03302260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CardioPrevent® Program
Description: This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
Study NCT05277597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.
Description: Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
Study NCT05277597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The same exercise training program without the sauna treatments
Description: The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
Study NCT00656136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients receive placebo once daily
Study NCT00656136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
Study NCT04367324 — intervention group
Intervention type: DEVICE
Intervention: Low-level laser therapy
Description: The low-level laser was applied to each patient in low-level laser therapy group.
Study NCT02362295 — intervention group
Intervention type: OTHER
Intervention: qualitative interview
Description: some patient are interviewed.
Study NCT03876509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Impedance Cardiography
Description: Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured.
Study NCT03285581 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: truSculpt RF
Description: Subjects will receive RF treatments
Study NCT03990168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: 1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
Study NCT03990168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fluency intervention/ Delayed Auditory Feedback
Description: Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
Study NCT03990168 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: fluency intervention/ Delayed Auditory Feedback
Description: Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
Study NCT03990168 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
Study NCT02539160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
Study NCT02539160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
Study NCT00386152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Description: 80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
Study NCT00386152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: 500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
Study NCT04881669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: obturator
Description: variable bulbs
Study NCT02861924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microcirculatory responses
Description: The effect of the duration and intensity of the pressure; reproducibility and correlation with ischemic hyperemia post.~measurements are made with the Imager SPECKLE imager (LSCI) give the microvascular perfusion data in arbitrary units called perfusion units (UP).
Study NCT03270969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate/Emtricitabine
Description: Participants will receive daily TDF/FTC for 14 days
Study NCT02512120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: volume controlled ventilation
Description: After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used.
Study NCT02512120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: autoflow-volume controlled ventilation
Description: After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used.
Study NCT02183948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02183948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01417949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time of starting antiretroviral therapy
Description: Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit.
Study NCT01112059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg twice a day for 8 days
Study NCT01112059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02251899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease-Management intervention
Description: The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
Study NCT01525017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combig-DC (allogeneic dendritic cells) Cancer Vaccine
Description: Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
Study NCT02953119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Study NCT02134990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D and Oshadi R
Description: Anti cancer agents
Study NCT03975881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application on smartphone
Description: The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
Study NCT03350763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tannenbaum 10 Fr biliary stent
Description: Tannenbaum 10 Fr biliary stent
Study NCT02134990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotheraphy
Study NCT01946932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temperature treatment
Study NCT01995513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth once daily
Study NCT01995513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg by mouth once daily
Study NCT01995513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: 1000 mg by mouth once daily
Study NCT01995513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Enzalutamide
Description: Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
Study NCT01995513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice daily
Study NCT01995513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg by mouth twice daily
Study NCT03893084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnancy preparation training
Description: Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
Study NCT01662687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso patch
Description: Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy.
Study NCT01662687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril inj.+Kytril tab.
Description: Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4.
Study NCT00200902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)
Description: Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
Study NCT00200902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
Study NCT00200902 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal Clinical Interaction (ICI)
Description: Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
Study NCT00611624 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mammosite brachytherapy radiation
Description: Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
Study NCT01403051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Description: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
Study NCT01403051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Study NCT01403051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Study NCT01403051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for calcium carbonate
Description: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Study NCT01403051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for vitamin D3
Description: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Study NCT02295501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTERCEPT Plasma
Description: Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
Study NCT03350763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expandable metallic biliary stent
Description: ie WallFlex biliary RX
Study NCT03166774 — intervention group
Intervention type: OTHER
Intervention: Program of support of the sexual health
Description: Patients included in the study have to answer to a questionnaire
Study NCT05096910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Closure with monofilament or polyfilament suture materials
Description: Postoperative 6th-month isthmocele rates
Study NCT02574598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-3475
Description: The dosing interval of pembrolizumab can be increased in case of toxicity.
Study NCT02574598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: The dosing interval of pembrolizumab can be increased in case of toxicity.
Study NCT02574598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Use on both arms as standard of care.
Study NCT02062385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V260
Description: V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)